Assuming that TAAR1 is the prospective therapeutic target for diseases associated with monoamine signaling disorders, we believe that TA signaling pathways should be kept in mind when developing new pharmaceutical approaches to managing metabolic syndrome. Here, TAAR1 is linked to metabolic syndrome.